



Prevention and control of three important avian disease **ND**、**IB** and **EDS**



Dr. Wang Fei

May. 2026

Quality Yield Health
品质成就健康



Dr. Fei Wang
Harbin Veterinary Research Institute, CAAS
China Agriculture University





Technical director of QYH.

Oversee QYH Poultry Disease Surveillance Center and vaccine production process optimization.

Focus on the research and development of genetically engineered vaccines, such as reverse genetic vaccines, live virus vector vaccines, recombinant protein vaccines, and therapeutic antibodies.

Undertake major vaccine R&D projects and published over 10 pieces of academic article on SCI-indexed journals, such as Science, Nature Communications.

CONTENT

-  **01. Epidemiology of ND, IB and EDS**
-  **02. Introduction of QVAC ND G7 vaccine**
-  **03. Introduction of QVAC ND+IB+EDS vaccine**
-  **04. Recommended vaccination program**





Newcastle Disease

- Newcastle disease is one of the most important poultry diseases worldwide, affecting a wide variety of birds and causing **significant economic loss** in the poultry industry.
- First discovered in Indonesia and Newcastle in the UK, 1926.



ND Neurological symptoms



Adenogastric papilla and
duodenal lymph node
hemorrhage



Yellowish-green watery feces



Bleeding from lymphoid
collections in the small intestine
and enlarged tonsils in the cecum



Newcastle Disease

Four major outbreaks of Newcastle disease


Number	Duration	Genotype
First	1920-1960	II、 III、 IV
Second	1960-1970	V、 VI
Third	1970-1980	VIb
Fourth	1980-now	VII

Vaccination is also the best way to reduce the losses.


01. Epidemiology of ND, IB and EDS




Newcastle Disease Virus



Structure of NDV



Structure of F protein



- At present, gene analysis based on NDV-related molecular epidemiological data shows that the genotype VII has become a major dominant against poultry industry in Egypt and other countries.

Newcastle Disease in Egypt

Epidemiological surveillance of Newcastle disease virus in Egypt — a 6-year cohort study


Khaled G. A. Abozaid^{1,2} · Ahmed S. Abdel-Moneim³

Received: 22 November 2021 / Accepted: 13 July 2022 / Published online: 1 August 2022
© The Author(s), under exclusive licence to Springer Nature B.V. 2022

Abstract

Newcastle disease (ND) is one of the most important poultry diseases worldwide and can lead to annual losses of up to 80% of backyard chickens in Africa. A retrospective cohort of 6 years was planned to screen the NDV in intensive chicken and turkey flocks. The existence of velogenic NDV strain was screened in different poultry flocks showing suspected signs of NDV using real-time RT-PCR targeting the F gene of the velogenic strain. A total of 843 poultry flocks were screened during the cohort. Samples were classified based on the month and year as well as the poultry type. All flocks should be negative for avian influenza virus as an inclusion criterion of the study. The F gene of a randomly selected positive sample from each year as well as an archival sample from 2005 was sequenced. An overall of 52.4% (443/842) of the tested farms showed positive results for the velogenic NDV. The cumulative percentage of positive flocks to the total positive flocks per month ranged from 5.9 to 11.8%. The results revealed that NDV is circulating across all months annually without evidence of seasonal tendency of the disease. **Most of the strains belong to genotype VII.1.1**, with only two strains related to XXI.1.1 and XXI.2. All VII.1.1 strains possess arginine at 27 position while XXI.1.1 and XXI.2 strains showed cysteine at 27 and amino acid substitutions in the signal peptide, cleavage site, and neutralizing epitopes. In conclusion, the current molecular epidemiological surveillance confirms the enzootic nature of NDV. It circulates all year round with no evidence of seasonal incidence. **Genotype VII is the most predominant NDV genotype in Egypt.**

Khaled, Ahmed S. 2022



01. Epidemiology of ND, IB and EDS



Newcastle Disease in Egypt

Evolution of Newcastle disease virus in Egypt.

Saad A. Moussa*, Mohammed Ahmed Mahmoud Abdullah**, Ehab E. Nabawy***

* Animal Health Research Institute, Agriculture Research Center (ARC), Egypt.

** Damanhur Branch, Animal Health Research Institute.

*** Dep. Of vet. Public health, Vet. Med. Faculty, Zagazig University.

Received in 11/10/2023
Received in revised from 1/11/2023
Accepted in 23/11/2023

Keywords:

Newcastle disease
protective immunity

ABSTRACT

In Egypt, Newcastle disease virus (NDV) outbreaks are occurring frequently, researchers try to study epidemiology of the virulent NDV isolates from these outbreaks. Velogenic & mild NDV strains was successfully isolated in Egypt from 1950 till now. NDV still reported to cause severe outbreaks with high losses in infected flocks during 2005, velogenic NDV caused outbreaks among commercial chicken in Egypt so, it is obligatory to study the protective immunity of commercially available vaccines for prevention and control of the disease. VIIb NDV genotype was previously described as the predominant sub-genotype of genotype VII circulating with severe outbreaks in Egypt in last decade.

Saad A., Mohammed, Ehab, 2023

Investigation of suspected Newcastle disease (ND) outbreaks in Egypt uncovers a high virus velogenic ND virus burden in small-scale holdings and the presence of multiple pathogens

Ibrahim Moharam^{1,2}, Alaa Abd el Razik³, Hesham Sultan⁴, Mohammed Ghezlan⁵, Clement Meseko⁶, Kati Franke⁷, Timm Harder⁸, Martin Beer⁹ and Christian Grund⁹

¹Institute of Diagnostic Virology, Friedrich Loeffler Institut, Greifswald - Insel Riems, Germany; ²Department of poultry disease, University of Sadat City, Sadat City, Egypt; ³Private poultry consultant, El Giza, Egypt; ⁴Virology Department, National Veterinary Research Institute, Vom, Nigeria; ⁵Institute of Infectology, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany

ABSTRACT

Highly contagious Newcastle disease (ND) is associated with devastating outbreaks with highly variable clinical signs among gallinaceous birds. In this study we aimed to verify clinical ND suspicions in poultry holdings in Egypt suffering from respiratory distress and elevated mortality, comparing two groups of ND-vaccinated poultry holdings in three governorates. Besides testing for Newcastle disease virus (NDV), samples were screened for infectious bronchitis virus (IBV) and avian influenza virus (AIV) by RT-qPCR as well as by non-directed cell-culture approach on LMH-cells. Virulent NDV was confirmed only in group A (n = 16) comprising small-scale holdings. Phylogenetic analysis of the fusion protein gene of 13 NDV-positive samples obtained from this group assigned all viruses to genotype 2.VIIb and point to four different virus populations that were circulating at the same time in one governorate, indicating independent epidemiological events. In group B, comparing large commercial broiler farms (n = 10), virulent NDV was not present, although in six farms NDV vaccine-type virus (genotype 2.8) was detected. Besides, in both groups co-infections by IBV (n = 10), AIV H9 (n = 3) and/or avian reovirus (ARV) (n = 5) and avian astrovirus (AAstV) (n = 1) could be identified. Taken together, the study confirmed clinical ND suspicion in small scale holdings, pointing to inefficient vaccination practices in this group A. However, it also highlighted that, even in an endemic situation like ND in Egypt, in cases of suspected ND vaccine failure, clinical ND suspicion has to be verified by pathotype-specific diagnostic tests.

ARTICLE HISTORY

Received 16 December 2018
Accepted 19 April 2019

KEYWORDS

Newcastle disease;
respiratory distress; co-
infection; diagnosis; Egypt;
epidemiology

Ibrahim, 2019

Molecular Characterization of Newcastle Disease Virus Genotype VII.1.1 from Egyptian Mallard Ducks with Nervous Manifestations

Mahmoud Ibrahim^{1*}, Mohamed A. Wahba², and Nahed Yehia³

¹Department of Birds and Rabbit Medicine, Faculty of Veterinary Medicine, University of Sadat City, 3298, Menoufia, Egypt

²Egyptian Company for Biological & Pharmaceutical Industries (Vaccine Valley), 6th October City, 12511, Giza, Egypt

³Reference Laboratory for Veterinary Quality Control on Poultry Production, Animal Health Research Institute, Agricultural Research Center, Dokki, Giza, 12618, Egypt


*Corresponding author's E-mail: mahmoud.jameel@vet.sac.edu.eg

Received: March 23, 2024. Revised: April 28, 2024. Accepted: May 16, 2024. Published: June 30, 2024

ABSTRACT


In Egypt, Newcastle disease virus (NDV) strains of genotype VII are known to be mild in domestic waterfowl and considered reservoirs. This is the first report for the detection of NDV GVII.1.1 from ducks showing severe clinical signs with high mortalities and nervous manifestations, additionally, isolation of NDV and molecular characterization for full HN and F genes were performed. In the current study, 16 backyard mallard duck flocks showing severe nervous signs with high mortalities were investigated by real-time RT-PCR using primers specific for the Fusion gene of NDV and matrix gene for avian influenza virus (AIV). Fourteen duck

Mahmoud, 2024






Infectious Brochitis Disease


- Infectious Brochitis Disease (IB) is a **highly infectious viral disease** of poultry that continues to inflict severe **economic damage** to the poultry industry.
- IBV belong to Coronavirinae, **Gammacoronavirus**.
- The infection may cause **various clinical forms** to the **respiratory system, digestive system, urinary system, and reproductive tract system**.
- Divided into **respiratory type, reproductive type, renal type, and proventriculus-lesion-inducing type etc.**



Infectious Brochitis Virus



01. Epidemiology of ND, IB and EDS



Genotype	Lineage	Frequency (At least)
GI	GI-1~GI-30	4280
GII	GII-1	79
GIII	GIII-1	4
GIV	GIV-1	157
GV	GV-1	7
GVI	GVI-1	124
GVII	GVII-1~GVII-2	13
GVIII	GVIII-1~GVIII-2	16
GIX	GIX-1	2
GX	GX-1	3
Total		4685

Infectious Brochitis Virus



Review

Infectious Bronchitis Virus in Egypt: Genetic Diversity and Vaccination Strategies

Hassanein H. Abozeid ¹ and Mahmoud M. Naguib ^{2,3,*}

- ¹ Department of Poultry Diseases, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt; h.abozeid@cu.edu.eg
- ² Reference Laboratory for Veterinary Quality Control on Poultry Production, Animal Health Research Institute, Agriculture Research Center, Giza 12618, Egypt
- ³ Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, 751 21 Uppsala, Sweden
- * Correspondence: Mahmoud.naguib@imbim.uu.se

Received: 17 November 2020; Accepted: 15 December 2020; Published: 17 December 2020



Abstract: Infectious bronchitis virus (IBV) is a highly evolving avian pathogen that has increasingly imposed a negative impact on poultry industry worldwide. In the last 20 years, IBV has been continuously circulating among chicken flocks in Egypt causing huge economic losses to poultry production. Multiple IBV genotypes, namely, GI-1, GI-13, GI-16, and GI-23 have been reported in Egypt possessing different genetic and pathogenic features. Different vaccine programs are being used to control the spread of the disease in Egypt. However, the virus continues to spread and evolve where multiple IBV variants and several recombination evidence have been described. In this review, we highlight the current knowledge concerning IBV circulation, genesis, and vaccination strategies in



Hassanein H.Abozeid, et al. 2020.

RESEARCH

Open Access



A full-length *S1* gene sequencing of a novel emerged GI-19 and GI-23 lineages of *Infectious bronchitis virus* currently circulating in chicken flocks in upper Egypt reveals marked genetic diversity and recombination events


Eman Shosha^{1*}, Sara Abdelnaser¹ and Ali Mahmoud Zanaty²

Abstract

Background *Infectious bronchitis virus* (IBV) is a highly contagious evolving pathogen that causes respiratory, urinary and reproductive symptoms; threatening the poultry industry globally.

Methods During this study, 90 tissue specimens were collected from various poultry flocks of seven Upper Egypt governorates from 2023 to 2024 for genetic characterization.



Result Typical IBV lesions of the inoculated embryos in the specific-pathogen-free-embryonated chicken eggs (SPF-ECE) were observed. Using real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assay targeting the conserved N gene, only 60 samples were considered positive with 66.6%. Collectively, 23 tissue specimens were examined through a one-step PCR assay. Sequencing is targeting the *S1* gene, and the phylogenetic analysis was conducted based on partial sequencing showed that *Avian coronavirus* (ACoV) isolates belong to GI-23 (n = 18), GI-12 (n = 2), GI-1 (n = 1), and GI-19 (n = 2). Genotyping of the *S1* gene indicates that GI-23 shows a genetic similarity to Egyptian isolates, and Israeli variants with nucleotide identity percentages (95–97%) and, (88–92%); respectively. Concerning full sequencing, five ACoV isolates were clustered as GI-23 (n = 3), and GI-19 (n = 2). Currently, QX-strains showed low genomic relatedness with Egyptian strains, and vaccinal strains with nucleotide (78–79%),



Eman Shosha, et al. 2025.



Egg Drop Syndrome

- Egg Drop Syndrome (EDS) is an infectious disease caused by **Egg Drop Syndrome Virus** (EDsV), characterized primarily by laying hens producing **thin-shelled** or **shell-less** eggs, and a significant decrease in egg production rate.
- EDS belong to **Group III** avian adenoviruses.
- Currently, this disease has become one of the major diseases causing egg production losses worldwide, resulting in huge economic losses to the poultry industry. This disease can reduce the egg production rate by **10%-30%**, with a maximum of **41%**, and the egg **breakage rate** can reach 38%-41%.





Egg Drop Syndrome Virus



Egg Drop Syndrome Virus

VETERINARY MICROBIOLOGY - RESEARCH PAPER



First report on genetic characterization of egg drop syndrome 1976 virus in Egypt

Emad Al-Ebshahy¹ · Mohammed AboElkhair² · Awad Shehata^{3,4} · Emad Elgendy⁵

Received: 27 November 2023 / Accepted: 30 September 2024 / Published online: 24 October 2024
© The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia 2024


Abstract

Since its first description in 1991 in Egypt, egg drop syndrome 1976 (EDS-76) virus has received a little attention as a potential cause for the drop in egg production as well as the reduction in egg quality. To date, no studies have been carried out to describe the genetic characteristics of the circulating field EDS-76 virus strains. Thus, the present study was attempted to estimate the emergence of EDS-76 virus in layer flocks and to determine the genetic diversity between the field strains and the vaccine strain 127. During 2022, a total of 5 apparently healthy backyard layer flocks were investigated for the presence of EDS-76 virus infection following complaints of sudden drop in egg production (25–30%), accompanied by high incidence of eggshell defects. EDS-76 virus DNA was detected in the oviduct samples of 4 (80%) flocks by polymerase chain reaction (PCR) assay targeting the hexon gene of the viral capsid. Attempts of viral isolation in duck embryo revealed no embryonic mortality, however, the allantoic fluids of inoculated eggs exhibited a sustained increase in the hemagglutinating (HA) activity throughout three consecutive passages. The obtained strain, designated BH-1, was characterized on the basis of partial hexon gene sequence analysis (GenBank accession number OR531368). The BH-1 strain displayed 99.6% nucleotide identity with the vaccine strain 127. However, amino acid alignments with the vaccine strain 127 revealed that the BH-1 strain carried 5 non-synonymous mutations. In addition, two of these mutations were incorporated into the hexon hypervariable regions (HVRs), which are strictly responsible for eliciting serotype-specific neutralizing antibodies. In conclusion, the present study represents a starting point for genetic characterization of EDS-76 virus in Egypt and highlights the importance for continuous monitoring and characterization of the circulating field EDS-76 virus strains, in order to determine the proper control strategy.




Emad Al-Ebshahy, et al. 2024.

Administration with vaccine is one of the best ways to prevent infectious disease.



02. Introduction of QVAC ND G7 Vaccine




QVAC ND G7

Newcastle Disease Virus Vaccine, Inactivated (A-VII Strain)






Newcastle Disease parent strain



**Velogenic Strain: ZJ1/00
Goose**



Vaccine parent Strain (ZJ1/00) belongs to genotype VII.




Newcastle Disease

Analysis of amino acid sequence in the antigenetic site of HN protein

Residues	203	340	342	347	494	495	508	509	514	570
V4 (I型)	Y	Y	D	E	G	V	S	T	I	G
LaSota (II型)	Y	Y	D	E	G	V	S	T	I	G
分离株 (VIIId型)	H	H	N	E/G/K/ D	D	E	N	I	V	R

The five antigen (193-201、345-353、513-521、494、569) regions and adjacent amino acids on the HN protein of the epidemic strain are significantly different from those of the Lasota vaccine strain.





Newcastle Disease

HI test of anti-LaSota serum with partial strains isolated in 2012 (log₂)


Serum	Virus strains								ZJ1/00
	LaSota	JS-09-12-Ch	JS-03-12-Ch	JS-04-12-Ch	JS-10-12-Ch	JS-11-12-Ch	JS-13-12-Ch	JS-05-12-Ch	
Anti-LaSota	9	6	7	7	6	6	6	6	6
Anti-NDV/VII	7	9	8	8	9	9	8	9	9

The HI test showed that some of the isolated epidemic strains in recent years have **significant antigenic differences** with the Lasota strain, and the titer of the Lasota strain's serum and self reaction is **4-8 times** higher than that of the epidemic strain.




Newcastle Disease

Generation of A-VII via attenuation



Hu S L, *et al.* Vaccine, 2009





Newcastle Disease


Identification of biological characteristics of A-VII recombinant viruses

Viruses	Pathogenicity		Allantoic fluids titer	
	MDT	ICPI	EID ₅₀ /0.1ml	HA
E1	>120h	0.3	10 ^{8.8}	10log ₂
E5	>120h	0.16	10 ^{9.17}	11log ₂
E10	>120h	0.22	10 ^{9.3}	11log ₂
E15	>120h	0.17	10 ^{8.8}	10log ₂

According to ICPI and MDT indicators, the virulence of A-VII strain is lower than that of Lasota strain, and it is safer to use as a vaccine strain. The virus was propagated in chicken embryos, the HA titer of A-VII strain can exceed 10log₂.



Newcastle Disease



The efficacy test results showed that the attenuated strain A-VII had **strong immunogenicity**, and its inactivated vaccine could produce high titers of HI antibodies when immunized with SPF chickens at a lower dose (**20ul**), and its induction rate of **antibody production was faster than LaSota**.

02.1 Development of QVAC ND G7 Vaccine



Newcastle Disease

Immune efficacy of NDV/A-VII in chickens

Frequency of isolation of challenge virus in commercial chickens


Group ^a	Post-challenge samples (no. positive/total)							
	Day 2		Day 4		Day 7		Day 10	
	O ^b	C ^c	O	C	O	C	O	C
PBS-C	10/10	10/10	10/10	10/10	NS ^d	NS	NS	NS
L-A-VII-C	8/10	3/10	1/10	3/10	0/10	1/10	0/10	0/10
L-Las-C	10/10	3/10	3/10	6/10	0/10	2/10	0/10	0/10
Oil-A-VII-C	5/10*	0/10	2/10	2/10	0/10	1/10	0/10	0/10
Oil-Las-C	9/10	0/10	4/10	4/10	1/10	0/10	0/10	0/10

^a C: challenged with 10⁵ ELD50 JS2/06.



^b O: Oropharyngeal swabs.

^c C: Cloacal swabs.


^d NS: no survivors.



Oropharyngeal



Cloacal






Newcastle Disease

A-VII vaccine strain have excellent characteristics

- A-VII MDT >120h, ICPI <0.3, its virulence is lower than that of Lasota strain.
- A-VII Virus titer >10⁹EID₅₀/0.1ml, HA >10log₂.
- The antigenicity of strain A-VII is completely **matched with** the epidemic strain, and its immunogenicity is very strong. It produces **2-3 log₂** higher HI antibodies than Lasota, and the antibody increases one week earlier. The virus shedding titer is reduced by **10-100 times** compared to Lasota.



HU S., MA H., WU Y., LIU W., WANG X., LIU Y. & LIU X. (2009). A virulent Newcastle disease virus generated by reverse genetics. *Vaccine*, 27 (10), 1044-1048.

KAPCZYNSKI D.R. & KING D.J. (2005). Protection of chickens against viral shedding following vaccination with commercially available Newc with highly virulent virus from the California 2002 exotic Newcastle 3433.

KARACA K., SHARMA J.M., WINSLOW B.J., JUNKER D.E., REDDY S., COCH fowpox viruses coexpressing chicken type I IFN and Newcastle disease on protective efficacy and humoral responses of chickens followed by recombinant viruses. *Vaccine*, 16 (16), 1496-1503.

OIE Terrestrial Manual 2012



Newcastle Disease



The First ND GVII Product in the world!

02.2 Characteristics of QVAC ND G7 Vaccine



99.2% F-protein Homology to Field Strains:

Precision Protection Against
Newcastle Disease Evolving



Rapid Antibody Response + Sustained Protection:

Dual-Shield Protection
Against Virus



Shedding Interception:

75% reduction of the ND
Virus shedding and
transmission

NDV A-VII: A Reverse Genetics-Engineered Newcastle Disease Virus Strain with Enhanced Attenuation & High Viral Yield

Developed through targeted modification of envelope glycoprotein genes and cleavage site mutagenesis in the F protein, the NDV A-VII strain achieves:

- High attenuation (ICPI = 0.16; MDT > 120h)
- Superior embryonated egg productivity
- Stable genetic profile

Patent Protected | CN101182494A



02.2 Characteristics of QVAC ND G7 Vaccine




Precisely engineered with reverse genetics targeting prevalent strains for stronger immunity vs. conventional vaccines (La Sota Strain).



Comparison of ND inactivated vaccine strains

Strain	Genotype	Virulent	Characteristics	Antigen content	Efficacy
A-VII Strain	VIIId	Non-pathogenic to chicks	High reproduction capacity High immunogenic	$10^{9.5} \text{EID}_{50}$	Effective protection from 14 dpi and lasts for 4 months
La Sota Strain	II	Non-pathogenic to chicks	Medium reproduction capacity Medium immunogenicity	$10^{8.0} \text{EID}_{50}$	Effective protection from 21 dpi and lasts for 2 months


Our vaccine can rapidly induce antibodies in chickens and geese, providing long-duration immunity.



The QVAC ND G7 immunized group demonstrated a 75% lower viral shedding load in cloacal and laryngotracheal samples compared to the La Sota group, as quantified through virological analysis.



02.2 Characteristics of QVAC ND G7 Vaccine



QVAC ND G7 provides protection to immunized chicken and goose flocks against infection by prevalent virulent strains of Newcastle disease virus, while also demonstrating effective efficacy against classic virulent strains of the disease.





Production Process

STEP 1 Antigen preparation

STEP 2 Antigen inactivation

STEP 3 Emulsify with suitable adjuvant

STEP 4 Filling

STEP 5 Sealing, capping and labeling

02.3 Production of QVAC ND G7 Vaccine



Antigen preparation

Virus Culture



Fully automatic inoculation system



Antigen preparation

Virus Harvest

Tip1 Fully automatic inoculation and harvesting technology

The first manufacturer to master automatic antigen inoculation and harvesting process in China.

Fully automatic inoculation and harvesting machine are introduced from Italy.





Antigen preparation

Virus Purification

Tip2 Antigen high-speed low-temperature centrifugal purification technology

After the antigen was harvested, it was purified with **high-speed and low-temperature centrifugation**, effectively remove impurities from the antigen.

The antigen recovery rate reached 98%, and the prepared vaccine has got good stability, low viscosity. It will be easy to inject and cause minimal side effects.





Antigen preparation

Virus Concentration

Tip3 Antigen low-temperature concentration process

Increase the content of antigen;

Ensure the vaccine has good potency;

During the process of antigen concentration, a **constant temperature cold water control system** is provided to control the whole process at 8 °C, effectively ensuring the quality of the antigen.



MILLIPORE ultrafiltration concentration system

Antigen Inactivation

Virus Inactivation

Tip4 Fully automatic inactivation system

The temperature is controlled at 37 °C during the inactivation process, and the rotational speed is also automatically controlled.

It ensures antigen inactivation completely and avoids the damage of virus immunogenicity caused by temperature changes.



Inactivation Tank

Emulsification

Tip5 Thermostatic emulsification technology

Over a period of 6 years, learned from Merial ST6 emulsification technology, we have developed an specific and advanced emulsification technology in China.

The vaccine will be emulsified for several times at low temperature.



02.3 Production of QVAC ND G7 Vaccine



Filling, Capping and Sealing



Safety test

Species	Study Description	Key Message
AA Broiler	5-day-old, 2 dose, observe for 21 days.	All the chickens are healthy living without any local or systemic adverse reaction caused by the vaccine. Their body weight increase is well.
Roman Layer	120-day-old, 2 dose, observe for all the laying period.	The egg production is normal. There is no egg production loss caused by the vaccine.




Potency test (AA Brolier)

Protective Efficacy Studies

Groups of 1-day-old or 7-days-old chickens were vaccinated with 0.15ml or 0.2ml of QYH and Other company inactivated vaccine.


ND	日龄				
	14d	21d	28d	35d	42d
QYH 1d	6.3	8.3	7.8	7.6	7.1
QYH 7d	6.4	9.1	8.1	8.2	8.0
A 1d	5.3	7.0	7.2	7.4	6.9
A 7d	5.3	6.8	7.8	7.6	7.9
Control	5.1	6.4	4.0	4.8	5.0



A-VII vaccine can produce **antibodies quickly** and stimulate **a high titers**.

Potency test (Roman layer)

Roman layer ND antibody levels after immunization at different ages




A-VII vaccine can produce **antibodies quickly** and stimulate **a high titers**.

02.5 Recommended vaccination program

- **For laying hens (0.2-0.5ml/dose, S/C):**



- **For broiler (0.2ml/dose, S/C):**
- **For goose (0.5ml/dose, S/C):**



- **NDV genotype VII has become a major dominant genotype in Egypt.**
- **99.2% F-protein Homology to field strains which give a good protection.**
- **Lower impurity protein, higher antigen content ,Mobil white oil adjuvant which can give a lower side effects, better and longer protection.**
- **Good stability, low viscosity which will be easy to inject and cause minimal side effects.**
- **Rapid antibody response + Sustained protection: can give dual-shield protection against virus.**
- **Shedding Interception: 75% reduction of the ND virus shedding and transmission.**
- **Best efficacy: Effective protection from 14 dpi and last for 4 months.**






This vaccine product was launched in **2015** and has been clinically used for **11** years. We have successfully controlled the prevalence of Newcastle disease, and there have been few outbreaks of Newcastle disease in recent years.

I hope that usage of this product can also quickly control the epidemic and reduce damage to the poultry industry in Egypt.





QVAC ND+IB+EDS




03.1 Characteristics of ND+IB+EDS vaccine




QVAC ND+IB+EDS (Lasota/M41/AV127)
Launched in Egypt in 2017

NDV



Lasota Strain: $\geq 3 \times 10^8$ EID₅₀/0.1ml

IBV



M41 Strain: $\geq 3 \times 10^6$ EID₅₀/0.1ml
Genotype I

EDSV



AV127 Strain: HA $\geq 1:30720$

Three prevalence virus which can give a broadly protection.


03.1 Characteristics of ND+IB+EDS vaccine



High-speed and low-temperature centrifugation



MILLIPORE ultrafiltration concentration system



保留时间	面积	面积百分比	峰高	峰高百分比
7.751	12997850	18.22	3952416	20.47
8.535	8145503	11.42	1618567	8.38
9.417	12954039	18.16	3571456	18.50
9.520	6952603	9.75	2217988	11.49
11.181	9867800	13.83	2651310	13.73
11.361	10638126	14.91	2741099	14.20
12.968	6538853	9.17	1809038	9.37
14.750	3242971	4.55	746534	3.87
总计	71337745	100.00	19308408	100.00

MARCOL-52(C18—C22)

The purified antigen, higher antigen content ,Mobil oil adjuvant which could loss side effects, provide better and longer protection.



03.1 Characteristics of ND+IB+EDS vaccine



Two-step low-temperature emulsification technology to ensure no loss of antigen, uniform vaccine particles, stable dosage form, and fast and uniform induction of antibodies.

Good stability, low viscosity which will be easy to inject and cause minimal side effects.



Safety Studies

Species	Study Description	Key Message
SPF chicken	3~6 weeks old, 2 dose, observe for 14 days.	All the chickens are healthy living without any local or systemic adverse reaction caused by the vaccine
Roman Layer	120-da-old, 2 dose, observe for all the laying period.	The egg production is normal. There is no egg production loss caused by the vaccine.

03.2 Efficacy of ND+IB+EDS Vaccine



Efficacy Studies (SPF Chickens)

Batch	Antigen	Antibody Titer										Average	Ratio
		1	2	3	4	5	6	7	8	9	10		
2025021	NDV	7	8	8	8	7	7	8	8	8	7	7.6	26
	IBV	3	3	3	2	4	3	3	4	3	2	3.0	
	IBV	8	8	8	8	7	8	8	7	7	8	7.7	
	EDSV	10	11	11	10	11	10	9	10	10	10	10.2	
2025033	NDV	8	8	8	8	8	7	8	7	8	7	7.7	26
	IBV	3	4	3	3	3	2	2	2	3	3	2.8	
	IBV	7	7	6	8	8	7	8	8	8	8	7.5	
	EDSV	11	10	10	10	11	11	10	10	10	10	10.3	

03.2 Efficacy of ND+IB+EDS Vaccine



Efficacy Studies (Roman layer)

Batch	Antigen	Antibody Titer										Average
		1	2	3	4	5	6	7	8	9	10	
2025025	NDV	12	13	12	11	12	12	12	13	12	13	12.2
	IBV	8	8	8	9	7	8	8	9	7	9	8.1
	EDSV	10	9	9	10	9	10	9	11	9	11	9.7

ND+IB+EDS vaccine can produce **antibodies quickly** and stimulate **a high titers** 21 days post vaccination.





Efficacy Studies (layer)

The Efficacy Evaluation of ND+IB+EDS inactivated vaccine produced by QYH company

Dr. Arash Qalyanchi Langerudi

Department of virology, Faculty of Veterinary Medicine, **Tehran University**

Material

Farm one: LSL chicken (90000 pieces)

1. Blood sampling before vaccination
2. Blood sampling 3 weeks after vaccination

Farm two: Hy-Line chicken (25000 pieces)

1. Blood sampling before vaccination
2. Blood sampling 3 weeks after vaccination

Farm three: Hy-Line chicken (35000 pieces)

1. Blood sampling before vaccination
2. Blood sampling 3 weeks after vaccination

Measuring ND, IB and EDS Titer for each group.

The results are as below:




03.2 Efficacy of ND+IB+EDS Vaccine




Efficacy Studies (layer)


Farm 1/Qom



Farm 2/Qom






Farm 3/Qom



ND+IB+EDS vaccine can produce **antibodies quickly** and stimulate **a high titers** 21 days post vaccination.

03.2 Efficacy of ND+IB+EDS Vaccine

Efficacy Studies (layer)



ND+IB+EDS vaccine can produce **antibodies quickly** and stimulate **a high titers** 21 days post vaccination.

03.3 Recommended vaccination program

- **For laying hens (0.5ml/dose, S/C):**



2~4 weeks before egg production
0.5ml

- **For broiler breeder (0.5ml/dose, S/C):**



2~4 weeks before egg production
0.5ml



- **Genotype IB and EDS127 has become a major dominant genotype in Egypt.**
- **Three prevalence virus in ND+IB+EDS vaccine can give a broadly protection against three avian disease.**
- **The purified antigen, higher antigen content, Mobil oil adjuvant which could loss side effects, provide better and longer protection.**
- **Good stability, low viscosity which will be easy to inject and cause minimal side effects.**
- **ND+IB+EDS vaccine can produce antibodies quickly and stimulate a high titers 21 days post vaccination without any egg production loss.**





Thank you for your attention!

China Animal Husbandry Industry Co. LTD

Add: Building No.16, Part Eight ABP, No.188, Southwest Fourth Ring road, Fengtai District, Beijing, China

Email: jinq@cahic.com hess@cahic.com

Tel: +86-10 83672069 +86-10 83672061

Fax: +86-10 63701278